Dr. Nageatte Ibrahim

Dr. Nageatte Ibrahim has over 12 years of oncology industry drug development experience at Merck and GSK. Dr. Ibrahim also has 9 years of faculty appointments; an Instructor of Medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute and an Adjunct Assistant Professor at Perlman School of Medicine/Abramson Cancer Center. Dr. Ibrahim's fore into industry began at GSK working on the dabrafenib/trametinib program and global approvals in melanoma. At Merck, Dr. Ibrahim was a Vice President of Global Clinical Development, Oncology, overseeing the strategy and execution for Keytruda and combinations across multiple tumor types and assets. In her early career at Merck, she led the pivotal global registration studies for Keytruda in front-line advanced melanoma and resectable melanoma which have been approved globally. Major accomplishments from Dr. Ibrahim's clinical development teams under her leadership include global approvals in Merkel cell, gastric, biliary, and hepatocellular cancers, resected Stage IIB and IIC melanoma, pediatric neurofibromatosis-1 (NF-1) as well as tumor agnostic indications for TMB-H expressing cancers and MSI-H/dMMR tumors. Dr. Ibrahim was also responsible for the development strategy of multiple assets, including in partnership with other companies, while at Merck. Her next role was in the biotech sector as CMO of Oncology at Innovent Biologics USA where she lead a global development team and built up the USA subsidiary, Fortvita Biologics USA. Dr. Ibrahim has a long and successful track record of building great teams, fostering an environment of learning and comradery, as well as mentoring and coaching future talent for leadership. She also served as the Scientific Advisor for the Melanoma Research Alliance.